Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ipilimumab
Drug ID BADD_D01190
Description Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4).[L12126] Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex.[L12126] Ipilimumab was granted FDA approval on 25 March 2011.[L12126]
Indications and Usage Ipilimumab is indicated to treat unresectable or metastatic melanoma, as an adjuvant in the treatment of cutaneous melanoma, to treat microsatellite-high or mismatch repair deficient metastatic colorectal cancer, or to treat hepatocellular carcinoma.[L12126] Ipilimumab with [nivolumab] is indicated to treat advanced renal cell carcinoma.[L12126]
Marketing Status approved
ATC Code L01FX04
DrugBank ID DB06186
KEGG ID D04603
MeSH ID D000074324
PubChem ID Not Available
TTD Drug ID D07BVI
NDC Product Code 0952-2327; 71124-0001; 0003-2328; 71124-0020; 71124-0021; 0003-2327; 71124-0022; 83157-2327
UNII 6T8C155666
Synonyms Ipilimumab | Anti-CTLA-4 MAb Ipilimumab | Anti CTLA 4 MAb Ipilimumab | Ipilimumab, Anti-CTLA-4 MAb | Yervoy | MDX 010 | MDX010 | MDX-010 | MDX-CTLA-4 | MDX CTLA 4
Chemical Information
Molecular Formula Not Available
CAS Registry Number 477202-00-9
SMILES Not Available
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Adrenal insufficiency05.01.02.001; 14.11.01.004--
Colitis07.08.01.001--
Dermatitis23.03.04.002---
Diarrhoea07.02.01.001--
Enterocolitis07.08.03.003--
Eosinophilia01.02.04.001--
Fatigue08.01.01.002--
Hepatotoxicity09.01.07.009; 12.03.01.008---
Hypopituitarism05.03.02.001--
Meningitis11.01.03.001; 17.06.03.001--
Nephritis20.05.02.001---
Neuropathy peripheral17.09.03.003---
Pericarditis02.06.02.001--
Pneumonitis22.01.01.006--
Pruritus23.03.12.001--
Rash23.03.13.001---
Immune-mediated adverse reaction10.02.01.044---
The 1th Page    1    Total 1 Pages